TriSalus Life Sciences, Inc. (NASDAQ:TLSIW) Sees Large Increase in Short Interest

TriSalus Life Sciences, Inc. (NASDAQ:TLSIW – Get Free Report) saw a significant increase in short interest in the month of October. As of October 30th, there was short interest totaling 16,244 shares, an increase of 48.9% from the October 15th total of 10,910 shares. Based on an average daily trading volume, of 1,308 shares, the short-interest ratio is currently 12.4 days.

TriSalus Life Sciences Stock Performance

TLSIW stock traded up $0.00 during trading on Tuesday, hitting $0.94. The company had a trading volume of 1,826 shares, compared to its average volume of 4,839. The business has a 50-day moving average of $0.87 and a 200-day moving average of $0.95. TriSalus Life Sciences has a one year low of $0.44 and a one year high of $1.85.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in TriSalus Life Sciences stock. State Street Corp purchased a new position in shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSIW – Free Report) in the second quarter, according to its most recent filing with the SEC. The firm purchased 610,963 shares of the company’s stock, valued at approximately $2,780,000.

TriSalus Life Sciences Company Profile

(Get Free Report)

TriSalus Life Sciences is a medical technology and therapeutics company focused on improving treatment delivery for patients with solid tumors, particularly tumors in the liver and pancreas. Its approach combines proprietary drug-delivery technology with the development of immunotherapies. The company’s TriNav® infusion system is designed to deliver therapies into tumors using its Pressure-Enabled Drug Delivery (PEDD) approach. TriSalus is also developing investigational therapies intended to work alongside its delivery platform; these therapies are not established treatments.

Further Reading

Receive News & Ratings for TriSalus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TriSalus Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.